Ensysce Biosciences, Inc. 8-K

What Happened
Ensysce Biosciences, Inc. announced a private financing that closed on April 6, 2026, generating $2.0 million in gross proceeds. Under a Purchase Agreement entered November 13, 2025 (and a Subsequent Purchase Notice dated April 2, 2026), the company issued 2,000 shares of Series B preferred stock, convertible into up to 4,363,636 shares of common stock, and warrants to purchase up to 8,727,273 shares of common stock. The company also issued warrants to purchase 261,818 shares to designees of its financial advisor. The company said it will file a registration statement for resale of the underlying common shares within three business days after closing.

Key Details

• Closing date: April 6, 2026; Purchase Agreement originally dated November 13, 2025; Subsequent Purchase Notice dated April 2, 2026.
• Gross proceeds: $2.0 million; estimated net proceeds ≈ $1.9 million for general corporate purposes, including development of TAAP and MPAR® programs and working capital.
• Securities issued: 2,000 shares of Series B Preferred (stated value per share increased from $1,100 to $1,200), convertible into up to 4,363,636 common shares.
• Warrants: 8,727,273 total (exercise price $0.55 subject to adjustment). Warrants split into 4,363,637 exercisable for 18 months and 4,363,636 exercisable for five years; an additional 261,818-warrant grant to advisor designees.
• Anti-dilution and adjustment features: Exercise and conversion prices are subject to customary anti‑dilution and broad adjustment provisions (including reductions if the company issues shares at a lower effective price); the conversion price was materially reduced pursuant to prior adjustment provisions.
• Ownership limits and covenants: Warrants include a Beneficial Ownership Limitation of 4.99% by default (9.99% if elected before issuance). While the Purchaser holds Preferred with an aggregate stated value ≥ $100,000, the company agreed to certain restrictions on issuing additional common-equivalent securities, Variable Rate Transactions, and other actions specified in the Purchase Agreement.
• Offering exemption: Securities were issued in a private placement under Section 4(a)(2) and Rule 506(b) of the Securities Act.

Why It Matters
This financing provides Ensysce with near-term cash (≈ $1.9M net) to fund operations and its TAAP and MPAR® development programs, reducing immediate liquidity pressure. However, the deal introduces significant potential dilution: large numbers of common shares may be issued on conversion and exercise, and anti-dilution adjustments can lower exercise/conversion prices if the company sells shares at lower prices in the future. Investors should note the resale registration filing (to be made) and the contractual limits the company accepted while the Purchaser holds preferred shares, which may constrain certain future financings or issuances.